Business Context and Reporting Period
Company: Isis Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: Isis is a biopharmaceutical company focused on RNA-based drug discovery, primarily utilizing antisense technology to inhibit disease-causing proteins. The company operates two segments: Drug Discovery and Development (antisense therapeutics) and the Ibis Division (TIGER technology for infectious disease identification). Isis has one approved product, Vitravene (for CMV retinitis), and a pipeline of 10 antisense products in various stages of development.
Key Financial Metrics
| Metric | 2004 | 2003 |
|---|---|---|
| Total Revenue | $42.6 million | $50.0 million |
| Net Loss | $(142.5) million | $(95.0) million |
| Net Loss Per Share (Basic/Diluted) | $(2.52) | $(1.73) |
| Research & Development Expenses | $118.5 million | $117.0 million |
| Cash, Cash Equivalents & Short-term Investments | $103.9 million | $215.5 million |
| Working Capital | $82.2 million | $194.0 million |
| Stockholders' Equity (Deficit) | $(72.1) million | $67.2 million |
| Long-term Debt & Capital Leases | $236.6 million | $213.4 million |
Note: The 2004 Net Loss includes a $32.4 million non-cash restructuring charge.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by $7.4 million (15%) compared to 2003. This was primarily due to the completion of Phase III clinical trials for Affinitak in 2003, which reduced revenue in 2004. This decline was partially offset by increased licensing revenue from Alnylam ($5.5 million) and Eyetech ($4.0 million milestones for Macugen).
- Increased Net Loss: The net loss widened by approximately $47.5 million. Key drivers included the $32.4 million restructuring charge, a $5.1 million non-cash impairment loss on the Alnylam investment, and decreased investment income due to lower cash balances.
- Liquidity Reduction: Cash and short-term investments dropped by over $111 million, driven by operating cash outflows, capital expenditures, and a $10 million equity investment in Alnylam.
- Equity Deficit: The company moved from positive stockholders' equity in 2003 to a deficit of $72.1 million in 2004, largely due to the accumulated net loss.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Strategic Reorganization: In late 2004, management decided to refocus resources on second-generation antisense drugs and the TIGER technology. This led to the discontinuation of lower-priority programs (ISIS 14803, ISIS 104838) and the planned closure of the Singapore R&D laboratory in Q1 2005.
- Cost Containment: The company expects to incur additional restructuring charges in Q1 2005 related to employee terminations and facility consolidation. Management anticipates these measures will significantly decrease cash usage in 2005.
- Liquidity Runway: Based on current operating plans, management believes resources are sufficient to meet requirements through at least mid-2007.
- Debt Obligations: A significant $95 million interest-free loan from Eli Lilly is due in August 2005. Isis has the option to repay this in cash or common stock at $40/share.
Risks and Contingencies
- Clinical Trial Failures: The company faces high risk regarding the success of clinical trials. Recent failures include Affinitak (NSCLC) and alicaforsen for Crohn's disease. Future failures could impair the ability to attract partners and generate revenue.
- Partner Dependency: Revenue is heavily concentrated. In 2004, 37% of revenue came from one partner (Eli Lilly) and 18% from another (SAIC/DARPA). Termination of these contracts could materially harm the business.
- Regulatory Approval: No guarantee exists that drug candidates will receive FDA approval. Delays or rejections would prevent commercialization.
- Legal Proceedings: Ajinomoto Co., Inc. filed a demand for arbitration in January 2005 regarding a 1994 license agreement, seeking an accounting of sums due (alleged minimum $3.9 million). Isis believes the claim is without merit but estimates a potential loss range of $0 to $2.1 million.
Investor Verification Checklist
- Debt Maturity: Verify the repayment strategy for the $95 million Lilly loan due August 2005 and the impact of potential stock conversion on dilution.
- Restructuring Costs: Monitor Q1 2005 filings for the magnitude of additional restructuring charges related to the Singapore closure and workforce reduction.
- Clinical Milestones: Track progress of key candidates: alicaforsen (Ulcerative Colitis Phase III), ISIS 113715 (Diabetes Phase II), and ISIS 301012 (Cholesterol Phase I/II).
- Partner Revenue Stability: Assess the renewal status of government contracts (DARPA, CDC, NIAID) which funded 28% of 2004 revenue.
- Legal Exposure: Review the status of the Ajinomoto arbitration and any potential impact on intellectual property rights.